3-amino-4,4,4-trifluoro-2-butenenitrile | 33561-24-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-amino-4,4,4-trifluoro-2-butenenitrile
• 英文别名: 3-amino-4,4,4-trifluorobut-2-enonitrile；3-amino-4,4,4-trifluorobut-2-enenitrile；3-aminobut-2-enenitrile
• CAS: 33561-24-9
• 化学式: C₄H₃F₃N₂
• mdl: MFCD16619160
• 分子量: 136.076
• InChiKey: KPJCZLYKGPDZAX-UHFFFAOYSA-N

物化性质

• 沸点：
  286.9±40.0 °C(Predicted)
• 密度：
  1.341

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-amino-4,4,4-trifluoro-2-butenenitrile 在 sodium hydrogensulfide 、 magnesium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3-amino-4,4,4-trifluorobut-2-enethioamide
  参考文献：
  名称：

  Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

  摘要：

  SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SVVI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.

  DOI：

  10.1021/acs.jmedchem.8b01318
• 作为产物：
  描述：

  4,4,4-三氟-3-氧代丁腈 在 甲酸铵 、 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 18.0h， 生成 3-amino-4,4,4-trifluoro-2-butenenitrile
  参考文献：
  名称：

  Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

  摘要：

  SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SVVI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.

  DOI：

  10.1021/acs.jmedchem.8b01318

文献信息

• 3-Cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases
  申请人：Barfacker Lars

  公开号：US20100240620A1

  公开（公告）日：2010-09-23

  The present application relates to novel aryl-substituted 3-cyano-5-thiazolyl- and 3-cyano-5-thiadiazolyl-1,4-dihydropyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

  本申请涉及新颖的芳基取代的3-氰基-5-噻唑基和3-氰基-5-噻二唑基-1,4-二氢吡啶，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造用于治疗和/或预防疾病的药物，特别是心血管疾病。
• [EN] SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF<br/>[FR] 5-AMINOPYRAZOLES SUBSTITUÉS ET LEUR UTILISATION
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010020363A1

  公开（公告）日：2010-02-25

  The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.

  本申请涉及新型取代的5-氨基吡唑化合物，其生产方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物产品的用途。
• [EN] FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMÉTHYL-1,4- DIHYDROPYRIDINE À SUBSTITUTION FLUORO ET LEURS MÉTHODES D'UTILISATION
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011042368A1

  公开（公告）日：2011-04-14

  The present invention relates to novel fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

  本发明涉及具有蛋白酪氨酸激酶抑制活性的新型氟代取代的3,5-二氰基-4-(1H-吲哚-5-基)-2,6-二甲基-1,4-二氢吡啶衍生物，以及其制备方法和用于治疗c-Met介导的疾病或c-Met介导的病况，特别是癌症和其他增生性疾病的用途。
• [EN] FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF<br/>[FR] 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES FLUORÉES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011042367A1

  公开（公告）日：2011-04-14

  The present invention relates to novel fluorinated 2,6-dialkyl-3,5-dicyano-4-(1H-indazol-5-yl)-1,4- dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met- mediated conditions, particularly cancer and other proliferative disorders.

  本发明涉及具有蛋白酪氨酸激酶抑制活性的新型氟代2,6-二烷基-3,5-二氰基-4-(1H-吲哚-5-基)-1,4-二氢吡啶衍生物，以及其制造方法和用于治疗c-Met介导的疾病或状况，特别是癌症和其他增殖性疾病的用途。
• [EN] FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF<br/>[FR] 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-MÉTHYL-1,4-DIHYDROPYRIDINES FLUORO-SUBSTITUÉES ET LEURS UTILISATIONS
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011069761A1

  公开（公告）日：2011-06-16

  The present invention relates to novel, fluoro-substituted 2-aryl-3,5-dicyano-4-(1H-indazol-5-yl)-6- methyl-l,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly Cancer and other proliferative disorders.

  本发明涉及具有蛋白酪氨酸激酶抑制活性的新型，氟代取代的2-芳基-3,5-二氰基-4-(1H-吲哚-5-基)-6-甲基-1,4-二氢吡啶衍生物，以及其制备方法和用于治疗c-Met介导的疾病或条件，特别是癌症和其他增殖性疾病的用途。